Pneumonia management
I'll start by reading the medical library skill, then search for comprehensive pneumonia management content.
Reading File
Now I'll run parallel searches across the medical library database and PubMed simultaneously.
Finding Sources
Finding Sources
Searching PubMed
"pneumonia" AND "management" AND "guidelines"
Excellent - found highly relevant sources including the 2026 ATS CAP guideline. Now let me read the key textbook sections in parallel.
Reading File
Reading File
Finding Sources
Reading Article
PMID: 40679934
Good data collected. Now let me read the key management sections from Goldman-Cecil and search for severity scoring and HAP/VAP content.
Reading File
Finding Sources
Finding Sources
Let me read the continuation of the Goldman-Cecil treatment section and the HAP/VAP section.
Reading File
Reading File
I now have comprehensive data. Let me compile the full pneumonia management guide.
Pneumonia Management
Overview
Pneumonia is a lung parenchymal infection producing fever, cough, sputum, pleuritic chest pain, and a pulmonary infiltrate. It is the most common infectious cause of hospitalization and death in the United States, with hospitalization rates rising steeply with age (1-2/1000 in young adults to ~40/1000 in those 85+).
Classification
| Type | Definition |
|---|---|
| CAP (Community-Acquired Pneumonia) | Acquired outside hospital or within 48 h of admission |
| HAP (Hospital-Acquired Pneumonia) | Develops ≥48 h after hospital admission |
| VAP (Ventilator-Associated Pneumonia) | Develops ≥72 h after mechanical ventilation onset |
| Aspiration Pneumonia | Caused by inhalation of oropharyngeal or gastric contents |
Key Pathogens
CAP
- Typical bacteria: S. pneumoniae (most common), H. influenzae, S. aureus, gram-negative bacilli (account for ~30% combined)
- Atypical: Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella (<5% each)
- Viral: Influenza, RSV, hMPV, SARS-CoV-2 (~20-30% of cases; higher during COVID)
- No pathogen confirmed: >50% of cases
HAP/VAP
- S. aureus (10-20%; 50% may be MRSA)
- Pseudomonas aeruginosa (10-20%)
- Enteric gram-negative bacilli (20-40%)
- Acinetobacter baumannii (5-10%)
- MDR rates are high: ~28-35% of Pseudomonas resistant to cefepime; 56-61% of Acinetobacter carbapenem-resistant
Step 1: Severity Assessment
Pneumonia Severity Index (PSI) - preferred
Points are assigned for demographics, comorbidities, and examination/lab findings:
| Factor | Points |
|---|---|
| Age (years) | +1 per year (men); -10 (women) |
| Nursing home resident | +10 |
| Cancer (non-skin) | +30 |
| Chronic liver disease | +20 |
| Heart failure | +10 |
| Cerebrovascular disease | +10 |
| Renal disease | +10 |
| Altered mental status | +20 |
| Respiratory rate ≥30/min | +20 |
| Temp <35°C or ≥40°C | +15 |
| Pulse ≥125/min | +10 |
| Arterial pH <7.35 | +30 |
| BUN >30 mg/dL | +20 |
| Na <130 mEq/L | +20 |
| Glucose >250 mg/dL | +10 |
| Hematocrit <30% | +10 |
| PaO₂ <60 mmHg or SpO₂ <90% | +10 |
| Pleural effusion | +10 |
Interpretation:
- Class I-III (≤90 points): outpatient management likely safe
- Class IV-V (>90 points): hospitalization indicated
-
130 points or CURB-65 >3: ICU/intermediate care
CURB-65 (simplified, for when labs unavailable)
One point each: Confusion, Urea >7 mmol/L, Respiratory rate ≥30, BP systolic <90 or diastolic ≤60, age ≥65
- 0-1: outpatient
- 2: consider admission
- 3-5: hospital/ICU admission
Step 2: Empiric Antibiotic Treatment
CAP - Outpatient
| Patient group | Recommended regimen | Duration |
|---|---|---|
| Otherwise healthy, no comorbidities | Amoxicillin OR Doxycycline OR Azithromycin (monotherapy) | 5 days |
| With chronic conditions / risk for drug-resistant organism | Respiratory fluoroquinolone (e.g., levofloxacin, moxifloxacin) monotherapy OR Amoxicillin-clavulanate / cefpodoxime / cefuroxime + azithromycin/clarithromycin/doxycycline | 5 days |
CAP - Inpatient (Non-severe, no MRSA/Pseudomonas risk)
- Respiratory fluoroquinolone monotherapy
- OR β-lactam (ampicillin-sulbactam, ceftriaxone, cefotaxime) + macrolide or doxycycline
CAP - Severe (ICU admission)
- Dual therapy: β-lactam + macrolide or respiratory fluoroquinolone
- If MRSA risk (prior parenteral antibiotics in last 90 days, prior MRSA infection): add vancomycin or linezolid
- A rapid negative nasal MRSA PCR has high negative predictive value and can guide withholding MRSA coverage
- If Pseudomonas risk: use antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, meropenem)
- Anaerobic coverage (clindamycin) only if lung abscess or empyema suspected - NOT routine
HAP / VAP
| Scenario | Empiric Regimen |
|---|---|
| Low MRSA risk, non-MDR | Piperacillin-tazobactam OR cefepime OR meropenem (monotherapy) |
| High MRSA risk | Add vancomycin or linezolid |
| MDR Pseudomonas or Acinetobacter risk | Dual antipseudomonal coverage or carbapenem |
| Inhaled antibiotics | Not routinely recommended; consider as adjunct only when limited systemic susceptibility in GNB pneumonia |
MDR risk factors for HAP/VAP: prior IV antibiotics in last 90 days, high-risk unit with >10-20% resistance rates, known prior MDR colonization, immunosuppression, structural lung disease.
Step 3: Antibiotic Duration
- CAP (most patients): minimum 5 days - extend only if clinical stability not achieved
- Suspected MRSA or Pseudomonas CAP: 7 days
- Non-ICU CAP that is clinically stable: 3 days of IV β-lactam may be adequate before switching to oral
- HAP/VAP: typically 7 days; de-escalate based on cultures
Clinical stability criteria: resolution of vital sign abnormalities (temp, HR, RR, BP), tolerating oral intake, normal mentation.
Step 4: Adjunctive / Supportive Therapy
Corticosteroids
- NOT recommended routinely in CAP
- Exception: refractory septic shock (hydrocortisone 200 mg/day for 4-8 days) - supported by some guidelines
- The 2026 ATS CAP Guideline addressed systemic corticosteroids as one of its four key updated questions
Viral Co-infection
- Influenza confirmed: give oseltamivir regardless of symptom duration + empirical antibacterials (high prevalence of bacterial co-infection)
- SARS-CoV-2 confirmed: withhold antibacterials unless bacterial co-infection suspected; use antivirals ± monoclonal antibodies for high-risk patients
Procalcitonin
- Professional societies recommend against using procalcitonin to decide whether to start antibiotics in suspected CAP
Oxygen / Respiratory Support
- Target SpO₂ ≥94%; use supplemental O₂, high-flow nasal cannula, or NIV as needed
- Mechanical ventilation for respiratory failure
Lung Ultrasound (2026 ATS update)
- The 2026 ATS CAP Guideline specifically evaluated lung ultrasound as a diagnostic tool - now an evidence-based alternative to chest X-ray in appropriate settings
Step 5: Prevention
| Vaccine | Target population |
|---|---|
| Pneumococcal vaccine (PCV15/PCV20/PPSV23) | Adults ≥65, immunocompromised, chronic disease |
| Influenza vaccine (annual) | All adults |
| COVID-19 vaccine | All adults (updated formulations) |
Additional prevention measures:
- Smoking cessation
- Good oral hygiene (reduces aspiration risk)
- VAP bundle: head-of-bed elevation 30-45°, oral chlorhexidine decontamination, minimize sedation, daily spontaneous breathing trials, avoid unnecessary reintubation
Complications to Monitor
| Complication | Frequency |
|---|---|
| Empyema | ~3-5% of hospitalized CAP |
| Acute atrial fibrillation | ~20-25% of hospitalized patients |
| Myocardial ischemia / worsening heart failure | Part of same 20-25% with cardiac events |
| ARDS | Higher risk in VAP/HAP, immunocompromised |
| 30-day mortality | ~15% for hospitalized CAP; VAP overall ~13% |
Key Recent Guideline Updates (2026)
The 2026 ATS CAP Practice Guideline (Jones et al., AJRCCM 2026; PMID 40679934) is the most current evidence-based framework. It specifically updated recommendations on:
- Lung ultrasound for CAP diagnosis
- Empiric antibacterials when a respiratory virus test is positive (i.e., whether to still give antibiotics)
- Antibiotic duration - shorter courses supported
- Systemic corticosteroids in CAP
The JRS 2024 guideline for adult pneumonia management (Mukae et al., Respir Investig 2025; PMID 40614556) provides parallel international perspective.
Sources: Goldman-Cecil Medicine, 26e; Fishman's Pulmonary Diseases and Disorders; Murray & Nadel's Textbook of Respiratory Medicine; Current Surgical Therapy, 14e | 2026 ATS CAP Practice Guideline (PMID 40679934)
This is a shared conversation. Sign in to Orris to start your own chat.